Skip to main content
Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes

Fig. 1

Time course of HbA1c, BMI, HOMA-IR, and log hsCRP in patients treated with daily DPP4 inhibitors and weekly omarigliptin. Red circles, omarigliptin; blue squares, daily DPP4 inhibitors (control group). Data are presented as mean ± SD. Group differences between control and omarigliptin were analyzed using repeated measures ANOVA (*p < 0.05, p = 0.73536, 0.2176, 0.01409, and 0.00712 for HbA1c, BMI, HOMA-IR, and log hsCRP, respectively)

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us